BOSTON (TheStreet) --
Xoma CEO Steven Engle -- serial destroyer of shareholder value -- finally resigned this week. For those keeping score, Engle has now blown up at two
biotech companies -- he was a disaster at La Jolla Pharmaceuticals before running
Xoma into the ditch. I called Engle one of the worst biotech CEOs of 2010 and have longed urged Xoma's directors and shareholders to kick the guy to the curb, so his exit this week is welcome news.
Unfortunately, it's probably too little to late to salvage anything of value from the Xoma wreckage that Engle leaves behind.
Xoma shares were up just 3 cents, or 1.5%, to $1.99 on Thursday morning, the first trading day after Engle's departure. That just shows you how beaten down and irrelevant Xoma has become to biotech investors. Adjusted for the 1-for-15 reverse stock split last year, Xoma trades for 13 cents -- that's down 54% since the reverse split took effect.
...
Weiter zum vollständigen Artikel bei
"TheStreet.com"